The claim that the virus is going to continue to mutate into worse and worse varieties has some 'splainin' to do.
For one thing, it fails to take into account that there ARE better vaccines in existence already which would be effective against any variant. Why? Because Novavax already has an effective vaccine that does no use the mRNA technology -- it uses their proprietary and very effective adjuvant that increases the efficacy of the vaccine, along with proteins from the spike protein (not the entire spike) AND proteins from the BODY of the virus. The spike may mutate, but the body of the virus will not -- so this vaccine will offer some protection from ANY form of the COVID virus.
Why, you ask, do we not have this vaccine already?
Because the small company Novavax was winning the vaccine race, which meant that Pfizer and Moderna would not get the billions of first-mover advantage. So the FDA rescinded the license of the U.S.-based manufacturing facility that Novavax had contracted to manufacture the drug. Then, the same day, they awarded that facility's manufacturing capability to Moderna.
Then, after a lost month or two trying to find another manufacturer, Novavax found a manufacturer in South Korea. But the FDA decided that they could not possibly put one of their employees at risk traveling to South Korea to inspect the factory, which had been authorized by the FDA for many other drugs, so, in order not to endanger one employee, they refused to inspect the factory -- thus setting Novavax back more months.
Of course, all the articles you read about Novavax talk about their "troubled history" of not being able to get the vaccine manufactured. They don't say WHY -- and the WHY is: Big Pharma did not want another, and better, vaccine out there, because it would hurt their profits.
And Novavax, like CYDY, can never criticize the FDA for trying to murder them, because they they would never get approval for any of their vaccines, including their new flu vaccine which is superior to the existing ones (32% more effective).
So -- back to the premise -- Novavax is just one of several better vaccines that are being developed. The so-called 2nd- and 3rd-generation vaccines are more slow to develop, especially thanks to the FDA's continued desire to throw stumbling blocks in front of small companies -- but eventually the better vaccines WILL be available. Maybe when certain shorts and "science writers" drive the small companies into accepting a bad deal from a Big Pharma, which will miraculously bring the vaccine to approval? Who knows.
Also, a recent study claims that there is a limit to how many more bad mutations there can be (bad from the standpoint of mammals who can get infected) -- as there are only a few other targets that would make the spike protein more able to evade the immune system.
So the idea that the virus is going to continue mutating to worse iterations forever seems to be unlikely.
And then there is Leronlimab. Ace in the hole.
For one thing, it fails to take into account that there ARE better vaccines in existence already which would be effective against any variant. Why? Because Novavax already has an effective vaccine that does no use the mRNA technology -- it uses their proprietary and very effective adjuvant that increases the efficacy of the vaccine, along with proteins from the spike protein (not the entire spike) AND proteins from the BODY of the virus. The spike may mutate, but the body of the virus will not -- so this vaccine will offer some protection from ANY form of the COVID virus.
Why, you ask, do we not have this vaccine already?
Because the small company Novavax was winning the vaccine race, which meant that Pfizer and Moderna would not get the billions of first-mover advantage. So the FDA rescinded the license of the U.S.-based manufacturing facility that Novavax had contracted to manufacture the drug. Then, the same day, they awarded that facility's manufacturing capability to Moderna.
Then, after a lost month or two trying to find another manufacturer, Novavax found a manufacturer in South Korea. But the FDA decided that they could not possibly put one of their employees at risk traveling to South Korea to inspect the factory, which had been authorized by the FDA for many other drugs, so, in order not to endanger one employee, they refused to inspect the factory -- thus setting Novavax back more months.
Of course, all the articles you read about Novavax talk about their "troubled history" of not being able to get the vaccine manufactured. They don't say WHY -- and the WHY is: Big Pharma did not want another, and better, vaccine out there, because it would hurt their profits.
And Novavax, like CYDY, can never criticize the FDA for trying to murder them, because they they would never get approval for any of their vaccines, including their new flu vaccine which is superior to the existing ones (32% more effective).
So -- back to the premise -- Novavax is just one of several better vaccines that are being developed. The so-called 2nd- and 3rd-generation vaccines are more slow to develop, especially thanks to the FDA's continued desire to throw stumbling blocks in front of small companies -- but eventually the better vaccines WILL be available. Maybe when certain shorts and "science writers" drive the small companies into accepting a bad deal from a Big Pharma, which will miraculously bring the vaccine to approval? Who knows.
Also, a recent study claims that there is a limit to how many more bad mutations there can be (bad from the standpoint of mammals who can get infected) -- as there are only a few other targets that would make the spike protein more able to evade the immune system.
So the idea that the virus is going to continue mutating to worse iterations forever seems to be unlikely.
And then there is Leronlimab. Ace in the hole.
5
